Sepragen Corporation

UNION CITY, CA · Biotech · Private

Automated compact chromatography systems for cGMP-compliant purification

Claim this profile

Follows are private to you and power your alerts

Updated · sepragen.com

Sector
Biotech
Headquarters
UNION CITY, CA
Latest Form D
$5M, Oct 2024
Total capital
$5.2M
Federal grants
$225K
1 award · 2017
Rank in peer group#15 of 22
Private capital raised
$5M
1 Form D · last Oct 2024
24 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
2
4 pending · first 2014
Rank in peer group#3 of 22

Capital timeline

20172018201920202021202220232024FEDERAL ↑EQUITY ↓Cumulative $5.2M$225K1st Form D$5M
2017201920212023FEDERAL ↑EQUITY ↓Cumulative $5.2M$225K1st Form D$5M

Latest events

  • Private capital raisedForm D · SEC · 1st filing$5M
  • Federal grantNSF · Phase I · STTR Phase I: Novel Wicking Matrix Bioreactor for Pluripotent and Progenitor Cell Expansion$225K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

88months

from Sepragen Corporation’s first federal award to its first private round.

First federal award · Jun 2017
NSF · $225K
First Form D · Oct 2024
$5M · 1st Form D
Awards before first raise
1 award

An association in public records, not a cause or a prediction.

Standing among 22 peers

Line = median

Biotech · Device

  • Federal grantsBelow median
  • Granted patents#3 · top 14%
  • Linked publications#2 · top 9%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Vinit SaxenaResearcherExecutive OfficerLinked by 1 patent · $225K in grants as PI

What it has protected

USPTO · 2 granted of 6
Show all 6 patent records

Recent research by its founders

  • Novel low shear 3D bioreactor for high purity mesenchymal stem cell production20216 cites
  • Antibody purification by radial flow chromatography with thoughts on its implementation into an intensification/integration model20210 cites
  • Insulin production from hiPSC‐derived pancreatic cells in a novel wicking matrix bioreactor20205 cites
  • Amplifier TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • Rapt TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • GeniPhys, LLCSimilar federal contract value in Biotech · null in contracts
  • A-Alpha Bio, Inc.Similar federal contract value in Biotech · null in contracts
  • Elektrofi IncSimilar federal contract value in Biotech · null in contracts
  • OMNICYTE, LLCSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .